Research material
VIP / Vasoactive Intestinal Peptide
Lyophilized immune-signaling research peptide for pathway review
VIP / Vasoactive Intestinal Peptide is a neuroimmune signaling peptide studied around VPAC receptors, smooth-muscle signaling, and epithelial models.
Support can confirm any currently available COAs or batch documentation for this product.
Request available documentsConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesFor laboratory research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, mitigate, or prevent disease.
Mantener sellado, frío, seco y protegido de los cambios de calor. Confirme el almacenamiento específico del producto a su llegada.
Empaquetado para estabilidad en tránsito con soporte de pedidos disponible para rutas en climas cálidos.
Batch-linked certificate support is available through the documentation desk.
Contexto de investigación
Perfil de investigación de VIP / Vasoactive Intestinal Peptide
Vasoactive intestinal peptide is a 28-amino-acid neuropeptide studied through the VPAC1 and VPAC2 receptors and cyclic-AMP signaling. Research spans smooth-muscle response, vascular signaling, epithelial and barrier function, neuroimmune communication, cytokine regulation, airway models, and gastrointestinal physiology. VIP is a short-lived signaling peptide, so stability, assay timing, receptor expression, and delivery conditions strongly influence experimental results. It is selected when a project requires a native VPAC-receptor ligand rather than a general immune or vascular peptide. Its broad physiological literature provides mechanism context but should not be converted into disease, treatment, or personal-use claims for a catalog material.
Mecanismo propuesto
Binds VPAC1 and VPAC2 receptors, activating Gs and cyclic AMP. Depending on tissue, this can produce smooth-muscle relaxation, vasodilation, altered epithelial secretion, and modulation of immune-cell cytokine signaling.
Efectos reportados en estudios
- Cell and animal studies report bronchodilatory, vasodilatory, epithelial, neuroprotective, and anti-inflammatory effects in selected models.
- Human physiology studies report vasodilation, changes in blood pressure or heart rate, flushing, and gastrointestinal or airway effects.
- VIP is rapidly degraded and has broad receptor distribution, making exposure, stability, and systemic effects difficult to control.
Criterios de investigación comunes
VPAC1 and VPAC2 potency, cyclic AMP, vascular tone, airway or intestinal smooth muscle, epithelial secretion, cytokines, barrier function, blood pressure, heart rate, and peptide stability.
Evidencia y limitaciones
Physiology and receptor mechanisms are well characterized, but short half-life and broad systemic actions limit translation of model results.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
What documentation can I request before ordering?
Before ordering, contact support with the product name, selected format, andu2014if availableu2014an order or batch reference to request available batch-linked documentation.
What should I confirm before ordering?
Compare the product name, listed amount, physical form, storage note, price, and documentation route. When the order arrives, match the product and lot or batch reference to the order record and available documentation.